• Myriocin and Ceramide: Reading SPT Perturbations

  2026-08-31

  Myriocin is a selective serine palmitoyltransferase inhibitor for dissecting how de novo ceramide synthesis shapes cellular injury and growth. This article connects cardiac remodeling evidence with a rigorous, causality-focused assay strategy for sphingolipid metabolism research.

• Carbapenemase Transmission in CREC Across Guangdong

  2026-08-30

  Chen et al. integrated gene localization, conjugation, mobile-element analysis, antimicrobial susceptibility testing, and ERIC-PCR typing to characterize carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae from eight Guangdong teaching hospitals. The high prevalence and transferability of blaNDM-1 emphasize the importance of combining molecular surveillance with infection-control and antimicrobial-stewardship strategies.

• CSBTA Pharmacokinetics in MASH: PK Variability

  2026-08-29

  This 2025 study integrates plasma pharmacokinetics, tissue distribution, cellular transport, microsomal metabolism, and receptor-mediated regulation to explain how MASH alters exposure to Corydalis saxicola Bunting total alkaloids. Its main practical implication is that disease state and repeated dosing can jointly increase systemic and hepatic accumulation, requiring pharmacokinetic-aware dose design.

• FGFR3 Inhibition in SLC26A2 Chondrodysplasia

  2026-08-29

  The reference study combines genetic deletion, an inducible postnatal mouse model, chondrocyte assays, and pharmacological intervention to show that excessive FGFR3 signaling contributes to SLC26A2-related chondrodysplasia. Its findings support NVP-BGJ398-mediated pathway inhibition as a preclinical strategy for improving chondrocyte differentiation and bone microarchitecture, while leaving clinical translation unresolved.

• Carrier-Platin and Rapid ROS-Driven Cancer Cell Death

  2026-08-28

  Liu et al. describe carrier-platin, a platinum nanotherapeutic that confines ultrasmall platinum particles within a poly(amino acids) carrier to generate a rapid intracellular reactive oxygen species burst. The resulting cancer-cell death is distinct from conventional platinum-induced apoptosis and ferroptosis, appears independent of DNA damage, and shows activity in multidrug-resistant models with limited systemic toxicity in preclinical testing.

• SERCA-ER Stress and Hematopoietic Stem Cell Mobilization

  2026-08-28

  The 2025 reference study identifies SERCA-mediated endoplasmic reticulum stress as a previously underdeveloped regulator of hematopoietic stem cell mobilization. Using BHQ in cellular and mouse models, the authors connect SERCA inhibition to the CaMKII-STAT3-CXCR4 axis, suggesting a mechanistic route for reducing bone marrow retention of HSCs.

• Cyclic di-GMP: Assay Design Across Two Systems

  2026-08-27

  Cyclic di-GMP is an intracellular second messenger with distinct bacterial and mammalian research applications. This guide translates recent antitoxin findings into practical, phase-aware assay design for biofilm biology, STING research, and cancer immunotherapy studies.

• Multiomics Maps Acute Liver Injury Treatment Modules

  2026-08-27

  The reference study integrates co-expression networks, transcriptomics, and proteomics to compare how bifendate and muaddil sapra affect acute liver injury induced by CCl4. Its principal contribution is a systems-level map linking treatment-responsive genes and proteins to immune, hepatitis, metabolic, and regulatory modules, while also distinguishing potentially broader regulatory effects of muaddil sapra.

• Lactate–GPR81 Signaling and Insulin-Independent Uptake

  2026-08-26

  A 2026 Cell Research study identifies L-lactate as a metabolite that promotes skeletal-muscle glucose uptake independently of insulin through the GPR81–FARP1–RAC1–GLUT4 axis. The work connects exercise-associated lactate production with glucose homeostasis and provides a mechanistic framework for studying alternative pathways in hyperglycemia and insulin resistance.

• Nelfinavir Mesylate: From HIV to Ferroptosis

  2026-08-26

  Nelfinavir Mesylate offers translational researchers more than a validated HIV-1 protease inhibitor: it is also a mechanistic probe for the DDI2–NFE2L1–ubiquitin-proteasome response to ferroptotic stress. This article outlines how to separate antiviral activity from proteostasis effects, design evidence-driven workflows, and evaluate the compound’s strategic value without overstating cross-domain findings.

• 10074-G5: Translating MYC Biology into Cancer Insight

  2026-08-25

  A translational perspective on using 10074-G5 as a c-Myc inhibitor to connect MYC/TERT/NFκB biology with rigorous cancer research, mechanistic assays, and preclinical tumor regression studies.

• NVP-BGJ398 Phosphate: FGFR3 Signal Logic

  2026-08-25

  NVP-BGJ398 phosphate connects FGFR1–3 target engagement with genotype-dependent cancer biology and FGFR3-driven skeletal phenotypes. This article focuses on causal assay design, evidence integration, and the limits of translating pathway inhibition across disease models.

• NVP-BGJ398 Phosphate: From Signal to Phenotype

  2026-08-24

  NVP-BGJ398 phosphate is a potent FGFR1–3 inhibitor for connecting phospho-signaling changes with cancer and skeletal phenotypes. This article presents a phenotype-first strategy for interpreting FGFR assays, with practical guidance grounded in SLC26A2-related chondrodysplasia research.

• Cy5 amine (non-sulfonated): Protocol Guide

  2026-08-23

  Cy5 amine (non-sulfonated) is a primary amine-functionalized Cy5 dye for labeling compatible activated biomolecules when an organic-solvent stock can be introduced into the reaction. It is water-insoluble, so it should not be used for direct aqueous labeling or for diagnostic and medical applications.

• HyperPFU™ high-fidelity DNA polymerase PCR Guide

  2026-08-22

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, or otherwise difficult DNA templates where standard PCR enzymes may produce errors or incomplete products. It is appropriate for blunt-ended cloning and sequence-focused workflows, but not for protocols requiring 3′-A overhangs or sticky-ended PCR products.

448 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page